A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein–coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: McDermott, David H., Liu, Qian, Velez, Daniel, Lopez, Lizbeeth, Anaya-O’Brien, Sandra, Ulrick, Jean, Kwatemaa, Nana, Starling, Judy, Fleisher, Thomas A., Priel, Debra A. Long, Merideth, Melissa A., Giuntoli, Robert L., Evbuomwan, Moses O., Littel, Patricia, Marquesen, Martha M., Hilligoss, Dianne, DeCastro, Rosamma, Grimes, George J., Hwang, Samuel T., Pittaluga, Stefania, Calvo, Katherine R., Stratton, Pamela, Cowen, Edward W., Kuhns, Douglas B., Malech, Harry L., Murphy, Philip M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2014
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983611/
https://ncbi.nlm.nih.gov/pubmed/24523241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-527226
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk